Squarepoint
TERN

Squarepoint’s Terns Pharmaceuticals TERN Stock Holding History

Squarepoint’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.5M Buy
275,350
+250,183
+994% +$10.3M 0.02% 877
2025
Q4 		$1.02M Buy
25,167
+12,433
+98% +$287K ﹤0.01% 2589
2025
Q3 		$95.6K Sell
12,734
-75,104
-86% -$480K ﹤0.01% 4119
2025
Q2 		$328K Buy
87,838
+1,110
+1% +$3.47K ﹤0.01% 3620
2025
Q1 		$239K Buy
86,728
+73,603
+561% +$301K ﹤0.01% 3902
2024
Q4 		$72.7K Sell
13,125
-40,393
-75% -$274K ﹤0.01% 4768
2024
Q3 		$446K Buy
+53,518
New +$440K ﹤0.01% 3185
2024
Q2 		– Sell
-71,361
Closed -$468K – 4644
2024
Q1 		$468K Buy
+71,361
New +$466K ﹤0.01% 3089
2023
Q3 		– Sell
-15,871
Closed -$139K – 4244
2023
Q2 		$139K Buy
15,871
+2,946
+23% +$34.3K ﹤0.01% 3300
2023
Q1 		$153K Buy
+12,925
New +$124K ﹤0.01% 2884

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Squarepoint's TERN Position: Q1 2026 in Review

Squarepoint increased its Terns Pharmaceuticals (TERN) stake by 994% in Q1 2026, buying an estimated $10.3M and bringing the position to 275,350 shares worth $14.5M. The position accounts for 0.02% of the portfolio, ranked #877.

Squarepoint first reported a position in TERN in Q1 2023 and has held it in 10 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Squarepoint held 275,350 shares of Terns Pharmaceuticals worth $14.5M as of Q1 2026.
  • Squarepoint bought 250,183 Terns Pharmaceuticals shares in Q1 2026, an estimated $10.3M.
  • Terns Pharmaceuticals made up 0.02% of Squarepoint's portfolio in Q1 2026, its #877 holding.
  • Squarepoint first reported a position in Terns Pharmaceuticals in Q1 2023 and has held it in 10 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.